Fortamet

Fortamet is a brand name of metformin, approved by the FDA in the following formulation(s):

FORTAMET (metformin hydrochloride - tablet, extended release; oral)

• 
  Manufacturer: ANDRX LABS LLC
  
  Approval date: April 27, 2004
  
  Strength(s): 1GM ^[RLD][AB], 500MG ^[AB2]

Has a generic version of Fortamet been approved?

A generic version of Fortamet has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Fortamet and have been approved by the FDA:

metformin hydrochloride tablet, extended release; oral

• 
  Manufacturer: LUPIN LTD
  
  Approval date: June 29, 2011
  
  Strength(s): 1GM ^[AB], 500MG ^[AB2]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fortamet. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Controlled release oral tablet having a unitary core
  Patent 6,099,859
  Issued: August 8, 2000
  Inventor(s): Cheng; Xiu Xiu & Chen; Chih-Ming & Jan; Steve & Chou; Joseph
  Assignee(s): Andrx Pharmaceuticals, Inc.
  A controlled release antihyperglycemic tablet that does not contain an expanding polymer and comprising a core containing the antihyperglycemic drug, a semipermeable membrane coating the core and at least one passageway in the membrane.
  
  Patent expiration dates:
  
  
  • March 20, 2018
    
    ✓ 
    Drug product
  
  



• 
  Controlled release oral tablet having a unitary core
  Patent 6,495,162
  Issued: December 17, 2002
  Inventor(s): Xiu Xiu; Cheng & Chih-Ming; Chen & Steve; Jan & Joseph; Chou
  Assignee(s): Andrx Pharmaceuticals, Inc.
  A controlled release antihyperglycemic tablet that does not contain an expanding polymer and comprising a core containing the antihyperglycemic drug, a semipermeable membrane coating the core and at least one passageway in the membrane.
  
  Patent expiration dates:
  
  
  • March 20, 2018
    
    ✓ 
    Drug product
  
  



• 
  Methods for treating diabetes via administration of controlled release metformin
  Patent 6,790,459
  Issued: September 14, 2004
  Inventor(s): Xiu Xiu; Cheng & Chih-Ming; Chen & Steve; Jan & Joseph; Chou
  Assignee(s): Andrx Labs, LLC
  A method for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at a 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.
  
  Patent expiration dates:
  
  
  • March 17, 2021
    
    ✓ 
    Patent use: METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION
  
  



• 
  Controlled release metformin compositions
  Patent 6,866,866
  Issued: March 15, 2005
  Inventor(s): Chen; Chih-Ming & Cheng; Xiu-Xiu & Jan; Steve & Chou; Joseph
  Assignee(s): Andrx Labs, LLC
  A composition for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.
  
  Patent expiration dates:
  
  
  • March 17, 2021
    
    ✓ 
    Drug product
  
  



• 
  Controlled release metformin formulations
  Patent 7,919,116
  Issued: April 5, 2011
  Inventor(s): Chen; Chih-Ming & Cheng; Xiu Xiu & Jan; Steve & Chou; Joseph
  Assignee(s): Andrx Labs, LLC
  Sustained release pharmaceutical formulations comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof are disclosed. The formulations provide therapeutic plasma levels of the antihyperglycemic drug to a human patient over a 24 hour period after administration.
  
  Patent expiration dates:
  
  
  • March 20, 2018
    
    ✓ 
    Drug product
  
  

See also...

• Fortomet Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Fortamet Consumer Information (Cerner Multum)
• Fortamet Advanced Consumer Information (Micromedex)
• Metformin Consumer Information (Drugs.com)
• Metformin Consumer Information (Wolters Kluwer)
• Metformin Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Metformin Solution Consumer Information (Wolters Kluwer)
• Metformin Consumer Information (Cerner Multum)
• Metformin Advanced Consumer Information (Micromedex)
• Metformin Hydrochloride AHFS DI Monographs (ASHP)